Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 1
2002 8
2003 9
2004 8
2005 10
2006 23
2007 27
2008 21
2009 21
2010 21
2011 25
2012 18
2013 31
2014 25
2015 46
2016 26
2017 28
2018 21
2019 18
2020 29
2021 39
2022 53
2023 34
2024 20

Text availability

Article attribute

Article type

Publication date

Search Results

509 results

Results by year

Filters applied: . Clear all
Page 1
Guideline of guidelines: management of recurrent urinary tract infections in women.
Kwok M, McGeorge S, Mayer-Coverdale J, Graves B, Paterson DL, Harris PNA, Esler R, Dowling C, Britton S, Roberts MJ. Kwok M, et al. Among authors: paterson dl. BJU Int. 2022 Nov;130 Suppl 3(Suppl 3):11-22. doi: 10.1111/bju.15756. Epub 2022 May 17. BJU Int. 2022. PMID: 35579121 Free PMC article. Review.
Effect of Piperacillin-Tazobactam vs Meropenem on 30-Day Mortality for Patients With E coli or Klebsiella pneumoniae Bloodstream Infection and Ceftriaxone Resistance: A Randomized Clinical Trial.
Harris PNA, Tambyah PA, Lye DC, Mo Y, Lee TH, Yilmaz M, Alenazi TH, Arabi Y, Falcone M, Bassetti M, Righi E, Rogers BA, Kanj S, Bhally H, Iredell J, Mendelson M, Boyles TH, Looke D, Miyakis S, Walls G, Al Khamis M, Zikri A, Crowe A, Ingram P, Daneman N, Griffin P, Athan E, Lorenc P, Baker P, Roberts L, Beatson SA, Peleg AY, Harris-Brown T, Paterson DL; MERINO Trial Investigators and the Australasian Society for Infectious Disease Clinical Research Network (ASID-CRN). Harris PNA, et al. Among authors: paterson dl. JAMA. 2018 Sep 11;320(10):984-994. doi: 10.1001/jama.2018.12163. JAMA. 2018. PMID: 30208454 Free PMC article. Clinical Trial.
Antimicrobial Resistance in ESKAPE Pathogens.
De Oliveira DMP, Forde BM, Kidd TJ, Harris PNA, Schembri MA, Beatson SA, Paterson DL, Walker MJ. De Oliveira DMP, et al. Among authors: paterson dl. Clin Microbiol Rev. 2020 May 13;33(3):e00181-19. doi: 10.1128/CMR.00181-19. Print 2020 Jun 17. Clin Microbiol Rev. 2020. PMID: 32404435 Free PMC article. Review.
Achromobacter Infections and Treatment Options.
Isler B, Kidd TJ, Stewart AG, Harris P, Paterson DL. Isler B, et al. Among authors: paterson dl. Antimicrob Agents Chemother. 2020 Oct 20;64(11):e01025-20. doi: 10.1128/AAC.01025-20. Print 2020 Oct 20. Antimicrob Agents Chemother. 2020. PMID: 32816734 Free PMC article. Review.
Multidrug-Resistant Bacteria in the Community: An Update.
van Duin D, Paterson DL. van Duin D, et al. Among authors: paterson dl. Infect Dis Clin North Am. 2020 Dec;34(4):709-722. doi: 10.1016/j.idc.2020.08.002. Epub 2020 Sep 30. Infect Dis Clin North Am. 2020. PMID: 33011046 Free PMC article. Review.
Culture-independent detection systems for bloodstream infection.
Peri AM, Harris PNA, Paterson DL. Peri AM, et al. Among authors: paterson dl. Clin Microbiol Infect. 2022 Feb;28(2):195-201. doi: 10.1016/j.cmi.2021.09.039. Epub 2021 Oct 20. Clin Microbiol Infect. 2022. PMID: 34687856 Review.
Acinetobacter baumannii: emergence of a successful pathogen.
Peleg AY, Seifert H, Paterson DL. Peleg AY, et al. Among authors: paterson dl. Clin Microbiol Rev. 2008 Jul;21(3):538-82. doi: 10.1128/CMR.00058-07. Clin Microbiol Rev. 2008. PMID: 18625687 Free PMC article. Review.
Extended-spectrum beta-lactamases: a clinical update.
Paterson DL, Bonomo RA. Paterson DL, et al. Clin Microbiol Rev. 2005 Oct;18(4):657-86. doi: 10.1128/CMR.18.4.657-686.2005. Clin Microbiol Rev. 2005. PMID: 16223952 Free PMC article. Review.
Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial.
Bassetti M, Echols R, Matsunaga Y, Ariyasu M, Doi Y, Ferrer R, Lodise TP, Naas T, Niki Y, Paterson DL, Portsmouth S, Torre-Cisneros J, Toyoizumi K, Wunderink RG, Nagata TD. Bassetti M, et al. Among authors: paterson dl. Lancet Infect Dis. 2021 Feb;21(2):226-240. doi: 10.1016/S1473-3099(20)30796-9. Epub 2020 Oct 12. Lancet Infect Dis. 2021. PMID: 33058795 Clinical Trial.
509 results